CF PharmTech buys back 10,500 H-shares at HKD 21.71 average; treasury stock climbs to 0.69 million shares

Bulletin Express05-07

CF PharmTech, Inc. filed a Next Day Disclosure Return showing that on 7 May 2026 it repurchased 10,500 H-shares on the Hong Kong Stock Exchange. The purchase price ranged from HKD 21.60 to HKD 21.86 per share, giving a volume-weighted average of HKD 21.71. Total consideration amounted to HKD 0.23 million.

Following the transaction, the number of issued shares (excluding treasury shares) fell from 301.55 million to 301.54 million, while treasury shares increased to 0.69 million. Total issued shares remained unchanged at 302.22 million.

The buy-back was executed under the repurchase mandate approved on 16 December 2025, which authorises the company to repurchase up to 30.22 million shares. To date, 0.69 million shares have been repurchased under this mandate, representing 0.23 % of the company’s issued share capital on the mandate date.

The board confirmed that the repurchase complied with all applicable Hong Kong Listing Rules and regulatory requirements. In accordance with HKEX Rule 10.06(3)(a), CF PharmTech is subject to a moratorium on issuing new shares or transferring treasury shares until 6 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132656687?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132656687","market":"hk","top_or_hot":-1,"title":"CF PharmTech buys back 10,500 H-shares at HKD 21.71 average; treasury stock climbs to 0.69 million shares","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. filed a Next Day Disclosure Return showing that on 7 May 2026 it repurchased 10,500 H-shares on the Hong Kong Stock Exchange. The purchase price ranged from HKD 21.60 to HKD 21.86 per share, giving a volume-weighted average of HKD 21.71. Total consideration amounted to HKD 0.23 million.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) fell from 301.55 million to 301.54 million, while treasury shares increased to 0.69 million. Total issued shares remained unchanged at 302.22 million.</p>\n<p>The buy-back was executed under the repurchase mandate approved on 16 December 2025, which authorises the company to repurchase up to 30.22 million shares. To date, 0.69 million shares have been repurchased under this mandate, representing 0.23 % of the company’s issued share capital on the mandate date.</p>\n<p>The board confirmed that the repurchase complied with all applicable Hong Kong Listing Rules and regulatory requirements. In accordance with HKEX Rule 10.06(3)(a), CF PharmTech is subject to a moratorium on issuing new shares or transferring treasury shares until 6 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech buys back 10,500 H-shares at HKD 21.71 average; treasury stock climbs to 0.69 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech buys back 10,500 H-shares at HKD 21.71 average; treasury stock climbs to 0.69 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-07 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. filed a Next Day Disclosure Return showing that on 7 May 2026 it repurchased 10,500 H-shares on the Hong Kong Stock Exchange. The purchase price ranged from HKD 21.60 to HKD 21.86 per share, giving a volume-weighted average of HKD 21.71. Total consideration amounted to HKD 0.23 million.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) fell from 301.55 million to 301.54 million, while treasury shares increased to 0.69 million. Total issued shares remained unchanged at 302.22 million.</p>\n<p>The buy-back was executed under the repurchase mandate approved on 16 December 2025, which authorises the company to repurchase up to 30.22 million shares. To date, 0.69 million shares have been repurchased under this mandate, representing 0.23 % of the company’s issued share capital on the mandate date.</p>\n<p>The board confirmed that the repurchase complied with all applicable Hong Kong Listing Rules and regulatory requirements. In accordance with HKEX Rule 10.06(3)(a), CF PharmTech is subject to a moratorium on issuing new shares or transferring treasury shares until 6 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1132656687","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132656687","pubTimestamp":1778155413,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. filed a Next Day Disclosure Return showing that on 7 May 2026 it repurchased 10,500 H-shares on the Hong Kong Stock Exchange. The purchase price ranged from HKD 21.60 to HKD 21.86...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech以平均21.71港元回购10,500股H股；库存股攀升至69万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. filed a Next Day Disclosure Return showing that on 7 May 2026 it repurchased 10,500 H-shares on the Hong Kong Stock Exchange. The purchase price ranged from HKD 21.60 to HKD 21.86 per share, giving a volume-weighted average of HKD 21.71. Total consideration amounted to HKD 0.23 million.\nFollowing the transaction, the number of issued shares (excluding treasury shares) fell from 301.55 million to 301.54 million, while treasury shares increased to 0.69 million. Total issued shares remained unchanged at 302.22 million.\nThe buy-back was executed under the repurchase mandate approved on 16 December 2025, which authorises the company to repurchase up to 30.22 million shares. To date, 0.69 million shares have been repurchased under this mandate, representing 0.23 % of the company’s issued share capital on the mandate date.\nThe board confirmed that the repurchase complied with all applicable Hong Kong Listing Rules and regulatory requirements. In accordance with HKEX Rule 10.06(3)(a), CF PharmTech is subject to a moratorium on issuing new shares or transferring treasury shares until 6 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132656687","isCrawlerRequest":true}